T 2585/18 (Exendin-4 sustained release composition/ALKERMES) of 10.10.2022

European Case Law Identifier: ECLI:EP:BA:2022:T258518.20221010
Date of decision: 10 October 2022
Case number: T 2585/18
Petition for review of: -
Application number: 11180259.1
IPC class: A61K 38/22 A61K 47/34 A61K 38/26 A61K 9/50 A61K 9/00 A61K 31/573 A61K 9/16
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: Polymer-based sustained release device
Applicant name: Alkermes Pharma Ireland Limited
Amylin Pharmaceuticals, LLC
Opponent name: PHARMATHEN S.A.
Teva Pharmaceutical Industries Ltd.
Board: 3.3.04
Headnote: -
Relevant legal provisions: European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 54 European Patent Convention Art 56
Keywords: Added subject-matter (no)
Novelty - main request (yes)
Insufficiency of disclosure (no)
Inventive step - (yes)
Catchword: -
Cited cases: T 0435/91 T 1697/12 T 1320/13 T 0061/14
Citing cases: -

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is maintained as granted.